Vice President, Research & Development
Diana Cepeda, PhD joined SparingVision as VP of Research and Development.
She leads nonclinical development for SparingVision’s gene therapy and gene editing drug candidates.
Previously, she was VP of Translational Biology at Kriya Therapeutics, where she played a key role in defining the company’s pipeline and shaping strategic directions for its ophthalmology therapeutic unit. Prior to Kriya, she held leadership roles at Adverum Biotechnologies, contributing to the development of Ixo-vec and the Blue Cone Monochromacy (BCM) program. She also conducted research at Stanford School of Medicine. Diana holds a PhD in Experimental Medicine from Karolinska Institute, an MSc from Uppsala University, and a BSc from the University of British Columbia. She is based in San Diego, USA.